Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01E-4 tuberculosis vaccine.

GSK692342 - GSK, Bill & Melinda Gates Foundation

http://www.ncbi.nlm.nih.gov/pubmed/42119392

Alemnew F Dagnew; Alexander C Schmidt; Amy Cinar; Erlina Burhan; Gavin Churchyard; Henry C Mwandumba; Lee Fairlie; Marla Curran; Monde Muyoyeta; Robert Noble; Videlis Nduba; Willem A Hanekom

May 13, 2026